Program
edaglutide alfa
A development code. Also written as “TG103”, “TG103 22.5 mg” and “TG103 15 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, led by CSPC Pharmaceutical Group.
Furthest: phase 3, since Aug 8, 202311 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 110 open or running | phase 3since Aug 8, 2023 | Jun 12, 2019 | none ahead |
- Named in CSPC Pharmaceutical Group’s own pipeline as
edaglutide alfa (TG103)
, phase 4, as of Aug 20, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2019First study: phase 1 study in HealthyFirst studyNCT03990090 · 32 enrolled · China
- Mar 3, 20212 phase 1 studiesNCT04790006, NCT04839744
- Apr 19, 2021Phase 1 study in Diabetes MellitusNCT04855292 · 48 enrolled · China
- Sep 14, 2021Phase 2 study in Diabetes Mellitus, Type 2NCT05063253 · 208 enrolled
- Mar 3, 2022Phase 2 study in OverweightNCT05299697 · 195 enrolled · China
- Apr 6, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05348122 · 240 enrolled · China
- Aug 8, 2023Phase 3 study in OverweightNCT05997576 · 675 enrolled · China
- Jan 11, 2024Phase 2 study in ObesityNCT06226090 · 314 enrolled · China
- Jan 23, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06235086 · 632 enrolled · China
- Feb 6, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06258148 · 465 enrolled · China
TargetBeta
“This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1 receptor agonist, in the management of overweight or obesity, to supp…”study summary, read by Claude · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06258148Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 23, 2026 | 465 |
| NCT06235086Diabetes Mellitus, Type 2 · China | 3 | Completed | Feb 3, 2026 | 632 |
| NCT06226090Obesity · China | 2 | Completed | Sep 26, 2024 | 314 |
| NCT05997576Overweight · China | 3 | Completed | Feb 17, 2025 | 675 |
| NCT05348122Diabetes Mellitus, Type 2 · China | 2 | UNKNOWN | Nov 1, 2023 | 240 |
| NCT05299697Overweight · China | 2 | UNKNOWN | Jun 30, 2023 | 195 |
| NCT05063253Diabetes Mellitus, Type 2 | 2 | UNKNOWN | Mar 2024 | 208 |
| NCT04855292Diabetes Mellitus · China | 1 | Completed | Dec 1, 2022 | 48 |
| NCT04839744Healthy Male Subjects · China | 1 | Completed | Jun 15, 2021 | 24 |
| NCT04790006Diabetes Mellitus, Type 2 | 1 | UNKNOWN | Mar 2022 | 54 |
| NCT03990090Healthy · China | 1 | Completed | Nov 11, 2020 | 32 |
How it is read
Names in the registry
- “TG103”, 5 entries
- “TG103 22.5 mg”, 3 entries
- “TG103 15 mg”, 2 entries
- “TG103 7.5 mg”, 1 entry
- “TG103 injection”, 1 entry
Codes read as this program: TG103.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 5 studies
- Obesity, 3 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.